Skip to main content
BOTANIX PHARMACEUTICALS LTD logo

BOTANIX PHARMACEUTICALS LTD — Investor Relations & Filings

Ticker · BOT ISIN · AU000000BOT2 ASX Manufacturing
Open in API
Filings indexed 1,209 across all filing types
Latest filing 2020-05-21 Proxy Solicitation & In…
Country AU Australia
Listing ASX BOT

About BOTANIX PHARMACEUTICALS LTD

https://botanixpharma.com/

Botanix Pharmaceuticals Ltd is a clinical-stage pharmaceutical company focused on the development and commercialization of novel topical treatments for serious skin conditions. The company utilizes its proprietary Permetrex™ skin delivery technology, which is designed to improve the delivery of active ingredients through the skin. Its primary product, Sofdra™ (sofpironium bromide), is an FDA-approved prescription topical gel for the treatment of primary axillary hyperhidrosis. The company's research and development pipeline also includes clinical-stage candidates for the treatment of acne, rosacea, and atopic dermatitis. Botanix aims to address significant unmet medical needs in dermatology by providing innovative therapeutic solutions with enhanced safety and efficacy profiles.

Recent filings

Filing Released Lang Actions
Notice of General Meeting/Proxy Form 33 pages 1.1MB
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled 'NOTICE OF GENERAL MEETING AND EXPLANATORY MEMORANDUM TO SHAREHOLDERS' and includes details about the date, time, and place of the meeting, agenda items including resolutions to be voted on, voting instructions, and proxy forms. It is a notice sent to shareholders to inform them about the upcoming general meeting and to solicit their votes on specific resolutions such as granting incentive options and amending the constitution. There is no financial data, earnings information, or detailed management discussion. The document is not a report itself but a meeting notice and explanatory memorandum. Therefore, it fits the category of Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings.
2020-05-21 English
Letter to Shareholders - General Meeting 3 pages 861.4KB
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a notice to shareholders about an upcoming General Meeting, including details on the meeting date, location, proxy voting instructions, and COVID-19 related arrangements. It explicitly states it is a "Notice and Proxy Form" for a General Meeting, not the meeting materials or results themselves. The document is about informing shareholders and soliciting proxy votes, which fits the definition of Proxy Solicitation & Information Statement (PSI). The document length is 9065 characters, which is consistent with a detailed notice and proxy form. There is no financial data, no voting results, no management discussion, or other report content. Therefore, the correct classification is PSI.
2020-05-21 English
Change of Director's Interest Notice MT 2 pages 200.9KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and details changes in securities holdings by a company director, including disposals and holdings before and after the change. It references ASX listing rules and the Corporations Act, indicating it is a regulatory disclosure of insider transactions. The content focuses on personal share transactions by a director, which matches the definition of Director's Dealing filings. The document length is 3762 characters, which is typical for such notices. There is no indication of financial results, management discussion, or other report types. Therefore, the document is best classified as a Director's Dealing report.
2020-05-10 English
Appendix 4C - Quarterly 10 pages 312.8KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Botanix Pharmaceuticals Quarterly Activities Report and 4C Quarterly Cash Flow Report' and is dated 30 April 2020. It provides detailed updates on clinical development programs, corporate activities, and financial cash flow data for the quarter ended 31 March 2020. The presence of the Appendix 4C Quarterly Cash Flow report, which is a regulatory requirement for Australian listed entities, confirms this is a quarterly report containing substantive financial data and analysis for a period shorter than a full fiscal year. The document is approximately 15,000 characters long, indicating it is a full report rather than a brief announcement. Therefore, this document fits the definition of an Interim / Quarterly Report (IR).
2020-04-29 English
FDA Grants BTX 1801 QIDP Designation Status 4 pages 283.5KB
Capital/Financing Update Classification · 95% confidence The document is an ASX/Media Release dated 24 April 2020 announcing that the US FDA has granted Botanix Pharmaceuticals a Qualified Infectious Disease Product (QIDP) designation for its antibacterial product BTX 1801. The content focuses on regulatory status updates, clinical study progress, and strategic pipeline opportunities. There are no financial statements, earnings data, or detailed financial analysis present. The document is a corporate announcement about regulatory and clinical development milestones rather than a financial report or detailed investor presentation. It does not fit categories like Annual Report, Earnings Release, or Investor Presentation. It is a regulatory announcement about product designation and clinical updates, which aligns best with the Capital/Financing Update (CAP) category as it relates to company progress on product development and regulatory milestones that impact company valuation and capital markets. The document length (10,407 characters) and content confirm it is a full announcement, not a brief notice or report publication announcement.
2020-04-23 English
Botanix Provides Update on Development Activities 5 pages 251.3KB
Capital/Financing Update Classification · 95% confidence The document is an ASX/Media Release dated 16 April 2020 from Botanix Pharmaceuticals providing an update on its development activities, including clinical trial results, prioritization of development platforms, cost reduction measures, and future plans. It discusses clinical study outcomes, strategic focus shifts, and operational updates but does not contain detailed financial statements or comprehensive financial performance data. It is not a full annual or interim report, nor is it a transcript, audit report, or regulatory filing. The content is consistent with a Capital/Financing Update as it includes information on cost reductions, cash reserves, and funding runway, which are typical of financing or capital structure updates. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2020-04-15 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.